WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products, announced that Howard Pien was elected to its Board of Directors at today’s Annual Meeting of Shareholders. The Company also announced that Stephen C. McCluski has been named Chairman of the Board, replacing former ImmunoGen CEO Mitchel Sayare, Ph.D., in this position. Dr. Sayare continues to serve on the Board as a director.
